Zynerba Pharmaceuticals Number Of Shares Shorted vs. EBITDA

ZYNEDelisted Stock  USD 0.36  0.01  2.70%   
Based on Zynerba Pharmaceuticals' profitability indicators, Zynerba Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Zynerba Pharmaceuticals' ability to earn profits and add value for shareholders.
For Zynerba Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zynerba Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zynerba Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zynerba Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zynerba Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Please note, there is a significant difference between Zynerba Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zynerba Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zynerba Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Zynerba Pharmaceuticals EBITDA vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Zynerba Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zynerba Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Zynerba Pharmaceuticals is rated below average in number of shares shorted category among its peers. It is rated below average in ebitda category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Zynerba Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Zynerba EBITDA vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Zynerba Pharmaceuticals

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
419.98 K
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Zynerba Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(34.62 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Zynerba EBITDA Comparison

Zynerba Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Zynerba Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Zynerba Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zynerba Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Zynerba Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Zynerba Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.

Zynerba Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Zynerba Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zynerba Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zynerba Pharmaceuticals' important profitability drivers and their relationship over time.

Use Zynerba Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zynerba Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zynerba Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Zynerba Pharmaceuticals Pair Trading

Zynerba Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Zynerba Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zynerba Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zynerba Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zynerba Pharmaceuticals to buy it.
The correlation of Zynerba Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zynerba Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zynerba Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zynerba Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Zynerba Pharmaceuticals position

In addition to having Zynerba Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Synthetics Thematic Idea Now

Synthetics
Synthetics Theme
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in Zynerba Stock

If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements
Stocks Directory
Find actively traded stocks across global markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope